Serological and molecular evidence of a plausible transmission of hepatitis E virus through pooled plasma.
OBJECTIVE
Recently, hepatitis E virus has been recognized as a new transfusion-associated risk; however, its efficiency of transmission through blood products requires further investigation. Asymptomatic viremia of short duration has been observed in blood donors from several European countries to the rate of <1:10,000 and HEV transmission in recipients of blood products has been documented in Japan and Europe. Although HEV RNA was detected in large plasma fractionation pools used for manufacturing of plasma derived products, HEV transmission has not been demonstrated so far. In this study, we investigated the possibility of HEV transmission in patients with thrombotic thrombocytopenic purpura whose treatment included up to 40 l of plasma exchange.


METHODS
Thirty-six TTP patients received either solvent-detergent-treated plasma prepared by pooling of 2500 single-donor or cryosupernatant plasma. Three samples were collected from TTP patients at time 0, 1 and 6 months post-treatment and tested for anti-HEV antibodies. Patients with HEV seroconversion were also tested for viremia by PCR.


RESULTS
Two of seventeen TTP patients treated with SDP showed serological evidence of HEV infection. The 1-month samples from these patients were also positive for HEV RNA. A distinct rise of anti-HEV IgG level was detected in two other TTP patients with weak pre-existing immunity to HEV; this observation is indicative of a possible immune response boost due to a breakthrough infection.


CONCLUSIONS
This work provides, for the first time, indirect evidence of HEV transmission by pooled plasma and warrants further studies.
Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, MB, Canada.
A
A
Andonov
G
G
Rock
L
L
Lin
J
J
Borlang
J
J
Hooper
E
E
Grudeski
J
J
Wu
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001483:Base Sequence; D017931:DNA Primers; D005260:Female; D006508:Hepatitis Antibodies / Q000097:blood; D016751:Hepatitis E / Q000097:blood / Q000635:transmission*; D016752:Hepatitis E virus / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010949:Plasma / Q000821:virology*; D010951:Plasma Exchange / Q000009:adverse effects*; D016133:Polymerase Chain Reaction; D011697:Purpura, Thrombotic Thrombocytopenic / Q000628:therapy; D012367:RNA, Viral / Q000097:blood; D055815:Young Adult
D017931:DNA Primers; D006508:Hepatitis Antibodies; D012367:RNA, Viral
HEV infection; Solvent-detergent-treated plasma pools; thrombotic thrombocytopenic purpura